News
Novo Nordisk Has Ended Its Wegovy Deal With Hims & Hers: Here's What Investors Need to Know
Novo Nordisk (NYSE: NVO) and Hims & Hers Health (NYSE: HIMS) announced they were collaborating to allow Hims & Hers to sell the weight-loss drug Wegovy. Novo Nordisk revealed on Monday that it will no longer work with Hims & Hers,
Novo Nordisk abruptly ended its partnership with Hims & Hers after the Danish drugmaker accused the telehealth company of ...
The loss of its ability to sell Wegovy is a significant hit to Hims & Hers' business. The massive drop today in its stock ...
Novo Nordisk had been providing Hims & Hers with the FDA-approved Wegovy, an injectable semaglutide used for weight loss ...
First, the stock has sliced through two support levels. Shares broke through their 50-day moving average on Monday for the ...
MarketBeat on MSN4h
Why Hims & Hers Stock Could Be a Multi-Bagger in the MakingIt’s not often that investors come across the kind of companies that can yield a multi-bagger investment over the years.
Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...
Zacks Investment Research on MSN5d
Hims & Hers Stock Jumps 85.1% in 3 Months: Is It a Buy Now?Hims & Hers Health, Inc.’s HIMS investors have been experiencing some short-term gains from the stock lately despite its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback